KRW 101900.0
(-3.04%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 712.33 Billion KRW | 53.22% |
2022 | 464.92 Billion KRW | -11.93% |
2021 | 527.92 Billion KRW | -3.49% |
2020 | 547.01 Billion KRW | 17.08% |
2019 | 467.2 Billion KRW | -10.51% |
2018 | 522.07 Billion KRW | 6.91% |
2017 | 488.34 Billion KRW | -11.11% |
2016 | 549.38 Billion KRW | 6.39% |
2015 | 516.38 Billion KRW | 51.83% |
2014 | 340.1 Billion KRW | 19.03% |
2013 | 285.72 Billion KRW | 32.98% |
2012 | 214.86 Billion KRW | 8.88% |
2011 | 197.34 Billion KRW | 7.96% |
2010 | 182.78 Billion KRW | 9.4% |
2009 | 167.08 Billion KRW | -5.22% |
2008 | 176.29 Billion KRW | -26.77% |
2007 | 240.73 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 770.57 Billion KRW | 8.14% |
2024 Q1 | 712.58 Billion KRW | 0.0% |
2023 Q4 | - KRW | -100.0% |
2023 Q2 | 521.82 Billion KRW | 5.57% |
2023 Q1 | 494.28 Billion KRW | 6.32% |
2023 FY | 712.33 Billion KRW | 53.22% |
2023 Q3 | 635.53 Billion KRW | 21.79% |
2022 Q4 | 464.92 Billion KRW | -2.91% |
2022 Q2 | 523.24 Billion KRW | -8.12% |
2022 Q3 | 478.85 Billion KRW | -8.48% |
2022 Q1 | 569.49 Billion KRW | 7.87% |
2022 FY | 464.92 Billion KRW | -11.93% |
2021 Q3 | 547.75 Billion KRW | -3.43% |
2021 FY | 527.92 Billion KRW | -3.49% |
2021 Q1 | 650.62 Billion KRW | 18.94% |
2021 Q4 | 527.92 Billion KRW | -3.62% |
2021 Q2 | 567.22 Billion KRW | -12.82% |
2020 Q3 | 537.86 Billion KRW | -8.29% |
2020 Q1 | 518.66 Billion KRW | 11.01% |
2020 Q2 | 586.45 Billion KRW | 13.07% |
2020 Q4 | 547.01 Billion KRW | 1.7% |
2020 FY | 547.01 Billion KRW | 17.08% |
2019 Q3 | 485.98 Billion KRW | 5.23% |
2019 Q1 | 598.38 Billion KRW | 14.62% |
2019 Q4 | 467.2 Billion KRW | -3.86% |
2019 FY | 467.2 Billion KRW | -10.51% |
2019 Q2 | 461.85 Billion KRW | -22.82% |
2018 Q3 | 520.13 Billion KRW | -4.23% |
2018 FY | 522.07 Billion KRW | 6.91% |
2018 Q1 | 542.43 Billion KRW | 11.08% |
2018 Q2 | 543.1 Billion KRW | 0.12% |
2018 Q4 | 522.07 Billion KRW | 0.37% |
2017 Q4 | 488.34 Billion KRW | -3.5% |
2017 FY | 488.34 Billion KRW | -11.11% |
2017 Q1 | 557.29 Billion KRW | 1.44% |
2017 Q2 | 515.06 Billion KRW | -7.58% |
2017 Q3 | 506.05 Billion KRW | -1.75% |
2016 FY | 549.38 Billion KRW | 6.39% |
2016 Q4 | 549.38 Billion KRW | -5.51% |
2016 Q3 | 581.41 Billion KRW | -3.12% |
2016 Q2 | 600.14 Billion KRW | 13.66% |
2016 Q1 | 527.99 Billion KRW | 2.25% |
2015 Q3 | 417.42 Billion KRW | 0.24% |
2015 Q2 | 416.43 Billion KRW | 9.5% |
2015 FY | 516.38 Billion KRW | 51.83% |
2015 Q1 | 380.3 Billion KRW | 11.82% |
2015 Q4 | 516.38 Billion KRW | 23.71% |
2014 Q3 | 289.07 Billion KRW | 1.25% |
2014 FY | 340.1 Billion KRW | 19.03% |
2014 Q1 | 289.46 Billion KRW | 1.31% |
2014 Q2 | 285.5 Billion KRW | -1.37% |
2014 Q4 | 340.1 Billion KRW | 17.65% |
2013 Q4 | 285.72 Billion KRW | 6.35% |
2013 Q1 | 251.91 Billion KRW | 17.24% |
2013 FY | 285.72 Billion KRW | 32.98% |
2013 Q2 | 251.48 Billion KRW | -0.17% |
2013 Q3 | 268.65 Billion KRW | 6.83% |
2012 Q1 | 178.66 Billion KRW | 0.0% |
2012 FY | 214.86 Billion KRW | 8.88% |
2012 Q4 | 214.86 Billion KRW | 2.66% |
2012 Q3 | 209.29 Billion KRW | -6.31% |
2012 Q2 | 223.39 Billion KRW | 25.03% |
2011 Q1 | 166.55 Billion KRW | -2.44% |
2011 Q2 | 172.16 Billion KRW | 3.37% |
2011 FY | 197.34 Billion KRW | 7.96% |
2011 Q3 | 174.57 Billion KRW | 1.4% |
2010 Q4 | 170.71 Billion KRW | 5.32% |
2010 Q1 | 159.46 Billion KRW | 7.65% |
2010 Q2 | 166.4 Billion KRW | 4.35% |
2010 FY | 182.78 Billion KRW | 9.4% |
2010 Q3 | 162.08 Billion KRW | -2.59% |
2009 Q2 | 156.98 Billion KRW | -4.23% |
2009 Q1 | 163.92 Billion KRW | 12.77% |
2009 FY | 167.08 Billion KRW | -5.22% |
2009 Q4 | 148.14 Billion KRW | 4.13% |
2009 Q3 | 142.26 Billion KRW | -9.38% |
2008 Q1 | 226.45 Billion KRW | 14.42% |
2008 Q3 | 159.76 Billion KRW | -28.39% |
2008 FY | 176.29 Billion KRW | -26.77% |
2008 Q4 | 145.36 Billion KRW | -9.02% |
2008 Q2 | 223.09 Billion KRW | -1.48% |
2007 Q3 | 221.6 Billion KRW | -4.08% |
2007 Q1 | 261.33 Billion KRW | 0.0% |
2007 Q2 | 231.03 Billion KRW | -11.6% |
2007 FY | 240.73 Billion KRW | 0.0% |
2007 Q4 | 197.91 Billion KRW | -10.69% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Yuyu Pharma, Inc. | 77.85 Billion KRW | -814.921% |
Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 23.388% |
Ildong Holdings Co., Ltd. | 707.09 Billion KRW | -0.741% |
HANDOK Inc. | 449.7 Billion KRW | -58.401% |
Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -731.487% |
Dong-A ST Co., Ltd. | 631.91 Billion KRW | -12.727% |
SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -4381.667% |
Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 16.375% |
Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -1230.761% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -246.004% |
Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -847.624% |
MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -381.979% |
Hana Pharm Co., Ltd. | 70.4 Billion KRW | -911.825% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -814.921% |
Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1855.025% |
REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -183.629% |
Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -222.755% |
JW Holdings Corporation | 827.51 Billion KRW | 13.918% |
Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -63.008% |
Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | -21.395% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -87.656% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -798.265% |
Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -918.096% |
Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -193.321% |
Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -115.668% |
Yuyu Pharma, Inc. | 77.85 Billion KRW | -814.921% |
Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -45.37% |
Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 16.98% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -87.656% |
Yuhan Corporation | 712.33 Billion KRW | 0.0% |
Jeil Pharma Holdings Inc | 477.81 Billion KRW | -49.084% |
Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -420.074% |
Suheung Co., Ltd. | 516.66 Billion KRW | -37.871% |
JW Pharmaceutical Corporation | 379.59 Billion KRW | -87.656% |
Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -360.952% |
Korea United Pharm Inc. | 89.96 Billion KRW | -691.792% |
CKD Bio Corp. | 170.76 Billion KRW | -317.156% |
Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -192.261% |
Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -351.828% |
Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1555.862% |
Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -798.265% |
Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | -12.619% |
Boryung Corporation | 373.1 Billion KRW | -90.92% |
Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -242.146% |
Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -246.004% |
JW Lifescience Corporation | 96.44 Billion KRW | -638.608% |